Plain-English translation of NCT07646639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination of treatments for locally advanced rectal cancer: short-course radiation therapy paired with chemotherapy (CAPOX), an immunotherapy drug called Sintilimab (which helps your immune system fight cancer), and interleukin-2 (a medication that boosts immune cell activity). The study will compare two different doses of radiation to see which works best and causes fewer side effects.
Standard treatment for advanced rectal cancer doesn't work well enough for all patients—some don't respond fully, and others experience serious side effects or the cancer returns. This trial exists to test whether adding immunotherapy medications to radiation and chemotherapy can help more patients achieve better results and preserve normal body function after treatment.
You likely qualify if…
You likely don't qualify if…
You would receive short-course radiation therapy (5 daily treatments over one week) combined with chemotherapy infusions and immunotherapy injections over several months. The study will randomly assign you to receive either standard-dose or low-dose radiation to compare which approach works best. You'll have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and watch for side effects. After completing this combination therapy, you would proceed to surgery as standard care for this type of cancer.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China